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Abstract
Background—The class IV alcohol dehydrogenase (ADH7, µ-ADH, σ-ADH) is important in the
metabolism of ethanol and retinol. ADH7 is the only ADH not expressed in liver, instead being
expressed mainly in the upper gastro-intestinal tract. Genome wide studies have identified
significant associations between single nucleotide polymorphisms (SNPs) in ADH7 and
alcoholism and cancer, but the causative variants have not been identified.
Methods—In vitro studies of gene expression by transient transfection into cell lines that express
endogenous ADH7 (CP-A cells) and that do not (HepG2 cells).
Results—We have identified transcriptional regulatory elements of ADH7 and observed
differences in the effects of variants on gene expression in CP-A cells and HepG2 cells. Two
haplotypes of the proximal promoter that differ in a single nucleotide at rs2851028, A7P-G and
A7P-A, have different transcriptional activities. There is an interaction between variants further
upstream and these proximal variants: upstream regulatory sequences generally showed a greater
increase or smaller reduction in activity when combined with the A7P-A promoter than with the
A7P-G promoter. A sequence located 12.5 kb upstream (7P10) can function as an enhancer. In
CP-A cells, both haplotypes of 7P10 increased A7P-A activity by 2.5-fold while having only 1.2-
fold effect on A7P-G. In HepG2 cells, the 7P10-TTT haplotype had no effect on the A7P-A
promoter but decreased A7P-G promoter activity by 50%, while the CTT haplotype increased
A7P-A activity by 50% but had no effect on A7P-G.
Conclusions—These complex interactions indicate that the effects of variants in the ADH7
regulatory elements depend on both sequence and cellular context, and should be considered in
interpretation of the association of variants with alcoholism and cancer.
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INTRODUCTION
The class IV alcohol dehydrogenase (ADH7, µ-ADH, σ-ADH), encoded by ADH7 is
expressed in the epithelial tissues of the upper aero-digestive tract down to the stomach
(Vaglenova et al., 2003, Moreno and Parés, 1991). ADH7 efficiently metabolizes ethanol to
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acetaldehyde (Yin et al., 1990, Kedishvili et al., 1995), a known toxin and carcinogen
(Salaspuro, 2009), and is particularly active at high ethanol concentrations such as those
found in the upper aero-digestive tract immediately after consumption (Yin et al., 2003).
ADH7 plays a role in the first-pass metabolism of alcohol (Yin et al., 1997, Han et al.,
1998). ADH7 also efficiently oxidizes retinol to retinal (Yin et al., 2003, Yang et al., 1994),
which is the precursor to retinoic acid, an important signaling molecule (Rhinn and Dollé,
2012) and anti-carcinogen (Siddikuzzaman et al., 2011). Adh7−/− mice show severe growth
and survival defects on a vitamin-A deficient diet (Deltour et al., 1999). The potential
interaction between the two substrates of ADH7 has been implicated in fetal alcohol
syndrome (Duester, 1991, de Sanctis et al., 2011), cancer of the upper aerodigestive tract
(Yokoyama et al., 2012, Fontanelli et al., 2013). ADH7 expression was reduced by nearly
50% in Barrett’s esophagus and esophageal adenocarcinoma specimens (Botelho et al.,
2010) indicating a physiological correlation between ADH7 and cancer.
Genome wide studies have identified associations of ADH7 with alcoholism, drug
dependence and cancer. A recombination hotspot within intron 7 of ADH7 divides the
region into two haplotype blocks (Han et al., 2005, Edenberg et al., 2006, Birley et al., 2008-
a). SNPs located in the 5’ haplotype block are associated with both blood alcohol and breath
alcohol concentrations, and account for approximately 18% of a major quantitative trait
locus within the ADH region influencing alcohol metabolism, or 11% of the total genetic
variance (Birley et al., 2008-a, Birley et al., 2009-b). The C allele of rs1154458, located in
intron 6 of ADH7, is linked to protection against alcoholism (Osier et al., 2004, Han et al.,
2005). Two ADH7 non-synonymous coding variants are known, rs1573496 (Ala92Gly) and
rs59534319 (Lys238Glu; rare to uncommon in most populations). The GG and CG
genotypes at rs1573496 confer a protective effect against cancers of the upper aero-digestive
tract (Wei et al., 2010, McKay et al., 2011, Hashibe et al., 2008), where ADH7 is expressed.
There is no reported association of rs59534319 with disease, although it is only 30 bp away
from the synonymous SNP rs971074, which is associated with a higher risk for drug
dependence (Luo et al., 2007, Levran et al., 2009). It is likely that many of these
associations reflect differences in regulation of expression, as has been found for other
complex diseases.
An understanding of the ADH7 regulatory regions and the effects of variants on regulation
can help interpret the association data and point toward likely causal variants. A 232 bp
proximal promoter of ADH7 is functional in HeLa, CV-1 (monkey kidney) and H4IIE-C3
(rat liver) cell lines (Kotagiri and Edenberg, 1998). Mutation of an AP-1 transcription factor
binding site significantly decreased promoter activity, indicating an important role for AP-1
in ADH7 gene regulation (Kotagiri and Edenberg, 1998). Multiple binding sites for C/EBP
transcription factors were identified. Co-expression with C/EBP-α or C/EBP-β led to
decreases in promoter activity (Kotagiri and Edenberg, 1998). Since these C/EBP
transcription factors are prominently expressed in the liver, the negative effect of C/EBP co-
expression suggests one mechanism that contributes to ADH7 not being expressed in the
liver. Other transcription factors, including the retinoic acid receptor family, STAT family
and HNF family proteins, are predicted by PROMO (Messeguer et al., 2002) to bind in the
ADH7 proximal region. The ENCODE HMR Conserved Transcription factor track
(Weirauch and Raney) also predicted binding sites for the transcription factors FOXO3 and
FOXJ2 in the 1.5 kb region immediately upstream of ADH7.
The goal of this study is to identify elements regulating ADH7 transcription and examine
how genetic variants affect regulation. Two human cell lines with contrasting ADH7
expression were chosen to study ADH7 gene regulation. CP-A epithelial cells, derived from
a non-dysplastic Barrett’s esophageal sample immortalized by hTERT (Palanca-Wessels et
al., 1998) express ADH7 endogenously. HepG2 human hepatoma cells (Knowles et al.,
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1980) do not express ADH7. We identified regulatory elements, including some with cell-
specificity, and detected interactions among them.
MATERIALS AND METHODS
Bioinformatics
The mammalian conservation track in the UCSC genome browser was used to identify the
regions of conservation between human and other vertebrates in the sequence upstream of
ADH7. Published literature and online databases including ALFRED (Rajeevan et al., 2012)
and HGMD (Stenson et al., 2009) were used to identify disease associated SNPs. Linkage
Disequilibrium (LD) data from the NCBI Hapmap database (The International HapMap
Consortium, 2010; Data Rel 27, Feb 09) and the 1000 genome database (The 1000 Genomes
Project Consortium, 2012; based on Ensembl v69, Oct 2012) were used to identify LD
between SNPs in the vicinity of ADH7 and disease-associated SNPs. The Hapmap and
dbSNP databases were used to identify naturally occurring haplotypes and the samples to
use as templates for obtaining them.
Cloning of test fragments and their variants
Two naturally occurring haplotypes of an 841 bp ADH7 proximal promoter (A7P-G/A; −19
to −859 bp relative to ADH7 translation start site in GenBank AAC51351.1) were generated
by PCR amplification from an anonymous human DNA sample using Invitrogen Platinum
Pfx polymerase (Life Technologies, Grand Island, NY; catalog 11708-013). The two
promoter haplotypes, A7P-A and A7P-G were cloned into HindIII and BglII sites in the
multiple cloning site of the pXP2 luciferase vector (Nordeen, 1988), oriented so that the
promoters drive luciferase expression. Restriction sites for NcoI, Acc65I, NotI and XhoI
were included in the forward primer of A7P to facilitate further subcloning. Fragments of
approximately 1 kb each extending12.5 kb upstream of the ADH7 gene were amplified from
human DNA using Invitrogen Platinum Pfx polymerase. DNA samples used as templates in
PCR amplification of naturally occurring haplotypes of 7P5, 7P6, 7P8 and 7P10 (Table 1)
were obtained from the Coriell Institute for Medical Research (Camden, New Jersey, USA).
Fragments 7P2 to 7P10 (except 7P6) were cloned into Acc65I and XhoI sites of pXP2
upstream of promoters A7P-G and A7P-A, and tested for effect on each promoter activity.
7P6 was cloned into NcoI and XhoI sites of pXP2 upstream of A7P-G and A7P-A. 7P10
sub-fragments were cloned into HindIII and XhoI sites upstream of A7P-A. 7P10 sub-
fragment E2 was cloned into HindIII and XhoI sites upstream of A7P-A in the reverse
orientation to make E2flip, and into ApaI and SwaI sites to make E2far. E2 was cloned into
HindIII and XhoI sites upstream of luciferase gene to make E2prom.
Cell culture and Transient transfections
HepG2 human hepatoma cells (HB-8065; ATCC, Manassas, VA) were cultured in MEM
(ATCC) with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 4 mM glutamine (Thermo
Scientific Hyclone, Waltham, MA) and 1× Penicillin and Streptomycin (Thermo Scientific
Hyclone) on cell bind surface plates (Corning Inc., Tewksbury, MA; CLS3296) at 37°C.
Transient transfections in HepG2 cells were done by seeding 0.8 × 105 cells per well in
Corning cell bind surface 12-well plates (Corning Inc., Tewksbury, MA; CLS3336). 24 h
after seeding, medium was changed and cells were transfected with 1.52 pmoles of test
DNA, 15 ng of pCMV β-galactosidase plasmid (Clontech, Mountain View, CA) and enough
pUC19 DNA to get a total DNA amount of 1 µg per well. 2 µl per well Fugene HD (Roche,
Indianapolis, IN) was used as the transfection reagent.
CP-A cells (ATCC, CRL-4027) are an hTERT immortalized cell line obtained from a non-
dysplastic Barrett’s Esophagus tissue. CP-A cells were cultured in Keratinocyte-SFM
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(Invitrogen, Carlsbad, CA; 17005-042, with each 500 ml supplemented with 25 mg Bovine
pituitary extract and 2.5 µg human recombinant epidermal growth factor supplied with the
medium) plus 10% FBS and 1% Penicillin-Streptomycin (ATCC, 30-2300) at 37 °C. For
transient transfections, CP-A cells were seeded at 3.75 × 105 cells per well in 12-well cell
bind plates (Corning Inc., Tewksbury, MA; CLS3336). Transfections were done 24 h after
seeding as described above.
Reporter gene assays
HepG2 cells were collected in ice cold 1× PBS (made from 10 × PBS solution; Fisher
Bioreagents, Hampton, New Hampshire; BP3994) 30 h after transfection. Cells were
centrifuged and the pellet was resuspended in 100 µl of 1× Reporter Lysis buffer (Promega,
Madison, WI; E3971). Cell lysates were prepared by repeated freeze-thaw cycles in dry ice
and water. Lysates were centrifuged to pellet cell debris and the supernatants transferred to
new tubes. Luciferase activity was measured on a Spectramax LS (Molecular Devices,
Sunnyvale, CA) using the Luciferase assay system (Promega, Madison, WI; E1501), with 20
µl of the extract. β-galactosidase assays were carried out with 5 µl extract using the Galacto-
Light System (Tropix, Bedford, MA).
CP-A cells were harvested 24 h after transfections by washing once with 1× PBS, and
scraping into 250 µl 1× Reporter lysis buffer. Lysates were then freeze-thawed repeatedly
and centrifuged to pellet down cell debris, as described above. 20 µl and 10 µl of CP-A cell
supernatant was used for luciferase and β-galactosidase assays respectively.
All test fragments were transfected in at least 3 independent experiments, with each
experiment having at least 3 replicates. Relative activity of a test construct was calculated by
normalizing each luciferase activity to the internal control β-galactosidase activity, to correct
for the transfection efficiency, and then calculating the ratio of normalized luciferase activity
of test fragment to that of the promoter haplotype driving the luciferase expression in the
construct. P-values were calculated using two-tailed t-tests of the normalized values.
RNA extraction and purification, real time PCR
HepG2 and CP-A RNA were extracted using Trizol (Life Technologies, Carlsbad) and
purified using the Qiagen RNeasy mini kit (Qiagen, Germantown, MD) following the
manufacturer’s protocol. DNA concentrations were determined by absorbance at 260 nm
using a Nanodrop spectrophotometer (Thermo Scientific, Waltham, MA). Superscript III
First-strand synthesis system (Invitrogen, Carlsbad, CA; 18080-051) was used to synthesize
cDNA from 1 µg RNA following the manufacturer’s protocol. qPCR assays were performed
using 10 µl of 2× Power SYBR Green mastermix (Life technologies, Carlsbad, CA;
4367659), 2 µl of 3 µM primers, 3 µl of 2× diluted cDNA and water in the StepOnePlus
Real-time PCR system (Life Technologies, Carlsbad, CA; 4376598). No RT and no DNA
controls were included in each experiment.
RESULTS
ADH7 proximal promoter variant rs2851028 and its effect on activity
There are two haplotypes of the 841 bp fragment that extends from −19 bp to −859 bp with
respect to the ADH7 translation start site, A7P-A and A7P-G, that differ at a single SNP:
rs2851028, at −628 bp (Figure 1). Both haplotypes were tested for promoter activity by
transient transfections in CP-A esophageal cells that express ADH7 and in HepG2 hepatoma
cells that do not (Table 2). These cells represent the complementary pattern of ADH7
expression seen in humans (Westerlund et al., 2007, Vaglenova et al., 2003). Both
haplotypes of the promoter fragment were active in both cell types (Figure 2). The promoter
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construct with the minor G allele was 1.6 - to 2-fold more active than the promoter with the
A allele. The empty vector p×P2 had no activity in either cell type.
Upstream regulatory regions
Conservation extended approximately 12.5 kb upstream of ADH7, with only patches of
conservation seen in the rest of the intergenic sequence between ADH7 and C4orf17, which
flanks the ADH gene cluster on one end. We therefore focused our studies on this 12.5 kb
region. Fragments of approximately 1 kb (Figure 1) were cloned upstream of the A7P-G and
A7P-A promoters and tested for effects on promoter activity by transient transfections.
Monomorphic fragments
Fragments 7P2, 7P3, and 7P4, together spanning from −798 bp to −3515 bp, did not have
any reported SNPs, nor did fragments 7P7 and 7P9 (Figure 1). These monomorphic
fragments showed different activity depending on which promoter haplotype they were
combined with and which cells they were tested in. Fragment 7P2 reduced activity of both
promoters by 10–15% in CP-A cells (Figure 3A) and reduced the activity of the A7P-A
promoter by a similar 20% in HepG2 cells, but had a significantly larger effect on A7P-G
activity in HepG2 cells (55% reduction) (Figure 3B). 7P3 significantly increased both
promoter activities in CP-A cells but had little effect on the activity of A7P-A in HepG2
cells, and significantly reduced activity of A7P-G (by 38%) in HepG2 cells. 7P4 had
stronger effects on the A7P-G promoter in both cells, but in different directions: it increased
A7P-A and A7P-G promoter activities in CP-A cells (by 15% and 40% respectively), while
decreasing both activities in HepG2 cells (by 20% and 35% respectively). In CP-A cells,
7P7 increased A7P-A activity but decreased A7P-G activity to a similar extent, whereas in
HepG2 cells it decreased both promoters, with a much stronger effect on A7P-G (Figure
3B). 7P9 had little effect on A7P-A activity in CP-A cells, but strongly decreased A7P-G
activity. In HepG2 cells, 7P9 decreased activity of both promoters, with a much stronger
effect on A7P-G.
Polymorphic fragments
Fragments 7P5, 7P6, 7P8 and 7P10 contain SNPs (Figure 1) in linkage disequilibrium with
variants having significant disease associations (Table 3) (Wei et al., 2010, Osier et al.,
2004, McKay et al., 2011, Levran et al., 2009, Hashibe et al., 2008, Han et al., 2005, Cadoni
et al., 2012, Birley et al., 2008-a, Birley et al., 2009-b). Transient transfections were done
with two naturally occurring haplotypes of each of these fragments cloned upstream of both
A7P-A and A7P-G promoters. 7P5-ATAC had no effect on either promoter activity in CP-A
cells (Figure 4A) while strongly reducing both promoter activities (about 50%) in HepG2
cells (Figure 4B). 7P5-GCGT showed both promoter-specific and cell-specific function: it
had no effect on A7P-A but decreased A7P-G activity by 20% in CP-A cells; in HepG2
cells, it increased A7P-A activity by 20% but decreased A7P-G activity by 40%.
Both 7P6 haplotypes decreased both promoter activities by 36–47% in CP-A cells (Figure
4A). In HepG2 cells (Figure 4B), 7P6-A reduced A7P-A activity by 20% with no significant
effect of 7P6-G. Both 7P6 haplotypes showed a dramatic 85% reduction of A7P-G activity.
The 7P8 haplotypes 7P8-GC and 7P8-AG increased A7P-A activity in CP-A cells by 40%
and 20% respectively but had nearly no effect on A7P-G (Figure 4A). In HepG2 cells
(Figure 4B), both 7P8 variants decreased A7P-A activity by 20% and A7P-G activity by
approximately 60%.
The 7P10 variants had the greatest positive impact on promoter activity. In CP-A cells, both
7P10 haplotypes increased the A7P-A promoter activity 2.3–2.4 fold (Figure 4A) while
having significantly smaller effects on A7P-G activity (1.1–1.3 fold). In HepG2 cells, 7P10-
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CTT increased A7P-A activity by 40% with no effect on A7P-G, and 7P10-TTT had no
effect on A7P-A but decreased A7P-G activity by 40% (Figure 4B).
7P10, which had the greatest effect on activity of the A7P-A promoter, was fragmented into
three partially overlapping sub-sequences (Figure 5A) to better localize the regulatory
element(s). Transient transfections in CP-A cells showed that one of the sub-fragments,
7P10-E2 had the strongest effect on promoter activity (Figure 5B), twice that of the whole
fragment. The other sub-fragments 7P10-E1 and 7P10-E3 had some activity, but less than
the whole fragment.
Given its location and relatively strong effect on promoter activity, 7P10-E2 was tested to
determine if it functioned as an enhancer (Figure 6A). It did not function alone as a promoter
(7P10-E2prom; Figure 6B). It did function nearly as well in either orientation (E2flip vs E2),
and when moved further away from the promoter, fulfilling characteristics of an enhancer
(Figure 6B).
DISCUSSION
We have identified elements regulating ADH7 promoter activity in physiologically relevant
cell systems, and observed functional differences in the activities of naturally occurring
haplotypes of both the promoter and upstream regulatory elements. There are cell-specific
differences, and also differences in how the upstream sequences affect the promoter with the
A allele at rs2851028 vs. the G allele. In CP-A cells, which express ADH7 endogenously,
some fragments increase activity of the promoter with the A allele more than they do the
promoter with the G allele, and others increase the A-promoter while decreasing activity of
the G-promoter. Most of the upstream fragments reduce promoter activity in HepG2 cells,
which don’t express endogenous ADH7, with a stronger effect on the promoter with the G
allele. Thus the effects of a particular regulatory polymorphism are complex, and depend
upon the sequence context of other polymorphisms and on cell type. This can complicate
interpretation of association data.
The pattern of linkage disequilibrium among the upstream variants and those associated with
diseases shows three distinct LD blocks (Table 3). Variants in block 1, which contains the
A7P promoter with rs2851028 and the upstream 7P5 fragment with rs1154473, are in strong
LD (r2 ≥0.8, D’ ≥0.9) with variant rs1154458, associated with alcoholism (Osier et al., 2004,
Han et al., 2005), rs2654849, associated with age of onset of regular alcohol use (van Beek
JH, 2010) and rs1154460, associated with upper aero-digestive tract (UAT) cancers (Oze et
al., 2009, Hakenewerth et al., 2011). The more active allele of the promoter, rs2851028-G, is
in LD with the C allele of rs1154458, which protects against alcoholism (Osier et al., 2004,
Han et al., 2005). This is analogous to the faster-metabolizing isoforms of ADH1B and
ADH1C, which have protective effects on risk for alcoholism and excessive drinking
(Thomasson et al., 1993, Hurley and Edenberg, 2012, Edenberg and Foroud, 2013, Chen et
al., 1999, Bierut et al., 2012). Though the 7P5 haplotypes have similar effects relative to
each promoter in CP-A cells, there is a potential synergistic interaction between the two
7P5-GCGT haplotype and rs2851028-A in HepG2 cells.
rs1154460, also in block 1, is associated with upper aerodigestive cancers, the risk
increasing with increasing alcohol consumption (Hakenewerth et al., 2011). In this case, it is
the less active A allele of rs2851028 that is in LD with the risk allele for cancer, rs1154460-
A; the cancer risk increased with increasing alcohol consumption (Oze et al., 2009,
Hakenewerth et al., 2011). The direction of affect is similar to the association of the less
active ADH1C*2 with cancer, with the risk increasing additively with alcohol consumption
(Xue et al., 2012, Peters et al., 2005, Bongaerts et al., 2011). Retinoic acid and its precursor
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retinol are anti-carcinogens (Siddikuzzaman et al., 2011) and signaling molecules (Rhinn
and Dollé, 2012) that are important for the maintenance of epithelial tissues (Osanai et al.,
2007) including those expressing ADH7. The two ADH7 substrates use the same active site
(Yin et al., 1997, Yang et al., 1994, Kedishvili et al., 1995, Yokoyama et al., 2012, Han et
al., 1998), so there is potential competition between them that could reduce the oxidation of
retinol in the presence of ethanol. Although there are other retinol dehydrogenases in the
super family that includes the medium chain enzymes (ADHs) and the short chain
dehydrogenase (SDR) family, ADH7 has the greatest efficiency for oxidation of retinol to
retinaldehyde (Parés et al., 2008). The importance of ADH7 has been shown both by
morphological changes including inflammation and intestinal metaplasia in the gastric
mucosa when ADH7 activity is reduced (Matsumoto et al., 2005) and by the severe growth
and survival defects when Adh7−/− mice are raised on a vitamin-A deficient diet (Deltour et
al., 1999).
Block 2 contains 6 upstream SNPs in fragments 7P5, 7P6, 7P8 and 7P10, located between
−4667 bp to –12578 bp. These upstream fragments affect regulatory function in a cell- and
promoter haplotype-dependent manner. The minor alleles of these SNPs are in LD with the
minor alleles of SNPs associated with the early stages of alcohol metabolism (Table 3)
(Birley et al., 2008-a, Birley et al., 2009-b).
The third LD block comprises the 7P10 enhancer SNP rs17589306, in LD with two SNPs
associated with cancer (Table 3) (Wei et al., 2010, McKay et al., 2011, Hashibe et al., 2008,
Cadoni et al., 2012) and drug dependence (Luo et al., 2007, Levran et al., 2009) but not, thus
far, with alcoholism or alcohol metabolism (Birley et al., 2008-a). One of these, rs1573496,
is a coding SNP associated with upper aerodigestive cancer (Wei et al., 2010, McKay et al.,
2011, Hashibe et al., 2008, Cadoni et al., 2012); it is in complete LD with the enhancer SNP
rs17589306. rs971074, a synonymous SNP, is associated with drug dependence (Luo et al.,
2007, Levran et al., 2009, Hakenewerth et al., 2011). The other non-synonymous coding
polymorphism rs59534319, 30 bp away from rs971074, is uncommon to rare in most
populations and no associations have yet been reported; it is, however, possible that it
contributes to the reported associations in this linkage block.
In a genome-wide study of alcohol dependence in Han Chinese, ADH7 was reported to be
hypomethylated in alcoholics, although the sites were not shown (Zhang et al., 2013). The
UCSC Genome Browser shows two sites of methylation in the proximal promoter region (at
bp −148 and −787) and one site in the enhancer region (at −12059, in 7P10-E2); these are
partially methylated in many cell types, including HepG2. None are at polymorphic sites,
and their effect on gene expression is not known.
Our study demonstrates that variants affecting ADH7 gene regulation show combinatorial
and cell-specific interactions. This highlights the complexity of interpreting the effects of
individual SNPs, because they are dependent upon other SNPs that are in cis. Detailed
analyses of haplotypes that are associated with alcohol-related traits will be needed to
identify which SNPs are functional and the consequences of different combinations of SNPs.
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Map of the ADH7 promoter and upstream fragments in chromosomal orientation, drawn to
scale, with promoter (black solid), monomorphic fragments (patterned) and polymorphic
fragments (not shaded). Transcription occurs right to left (arrow) from the translation start
site (TSS). SNPs are shown, with the three LD blocks represented as solid black circles,
plain circles or grey circle.
Jairam and Edenberg Page 12














ADH7 promoter haplotypes are active in both CP-A and HepG2 cells. The relative activity is
the ratio of promoter activity of the G construct (A7P-G) to the A construct (A7P-A) within
each cell line. Standard errors of mean are shown (n≥12). P-value was 3 × 10−5 (HepG2
cells) and 1 × 10−6 (CP-A cells).
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Activity of monomorphic fragments on the two promoter haplotypes. Transient transfections
of the monomorphic upstream sequences 7P2, 7P3, 7P4, 7P7 and 7P9 were done in A) CP-A
cells and B) HepG2 cells. Relative activity of each construct represents the ratio of
normalized luciferase activity of the test fragment to the A7P-A (black) promoter or A7P-G
(grey shaded). Scales of vertical axes are different. Error bars represent standard errors of
mean. * indicate p-values ≤ 0.01; ** indicate p-values ≤ 1 × 10−5.
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Activity of polymorphic fragments on the two promoter haplotypes. Transient transfections
of two naturally occurring haplotypes of each polymorphic fragment (7P5, 7P6, 7P8 and
7P10) were done in A) CP-A cells and B) HepG2 cells. Each sequence was tested for effect
on both promoters A7P-G and A7P-A. Relative activity of each construct represents the
ratio of normalized luciferase activity to the promoter on which it was tested, A7P-G (grey
shaded) or A7P-A (black). Error bars represent standard errors of mean. Scales of vertical
axes are different. Relative activities are shown with * indicating p-values ≤ 0.008; **
indicate p-values ≤ 1 × 10−4
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Localization of regulatory elements in fragment 7P10. A) 7P10 sub-fragments
approximately 500 bp in size are shown as oriented on the chromosome, with E1 being the
farthest upstream from ADH7. B) Activity of sub-fragments of 7P10 in CP-A cells.
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Fragment 7P10 acts as an enhancer. A) Map of the p×P2 vector construct with E2 or E2flip
(E2 in reverse orientation) cloned into the HindIII and XhoI sites immediately upstream of
A7P drawn to scale. E2far contains E2 cloned into the ApaI and SwaI sites 3.5 kb away
from the promoter to test for position effects. B) 7P10-E2 tested for promoter activity
(E2prom) and enhancer properties, orientation independence (E2flip) and position
independence (E2far), by transient transfections in CP-A cells. Activity was measured
relative to A7P-A. Error bars represent standard error of means. All p-values ≤ 1 × 10−8
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Table 2
ADH expression in HepG2 and CP-A cells
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Table 3
Upstream SNPs in LD with disease associated SNPs
Upstream SNPs in LD with disease associated SNPs and the test fragments containing them are listed. SNPs
with r2 ≥ 0.8, D’ ≥ 0.9 are defined as within an LD block. The disease phenotypes associated with each SNP
are listed, along with the references.









rs1154458- Protection against alcoholism (Han et al., 2005, Osier et al., 2004)
rs2654849- Age at onset of regular alcohol use (van Beek JH, 2010)













rs1154461- Alcohol metabolism (Birley et al., 2009, Birley et al., 2008)
rs1154468- Alcohol metabolism
rs894363- Alcohol metabolism
rs1154470- Alcohol metabolism; Extraversion and conscientiousness in Substance-dependent
subjects (Luo et al., 2008)
3 rs17589306 7P10 rs971074- Drug dependence & heroin addiction (Luo et al., 2007, Levran et al., 2009),
rs1573496- UAT cancer (Hashibe et al., 2008, McKay et al., 2011, Wei et al., 2010, Cadoni and
Pandolfini, 2012)
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